CL2019000485A1 - Uso de pridopidina para el tratamiento de la disminución funcional. - Google Patents

Uso de pridopidina para el tratamiento de la disminución funcional.

Info

Publication number
CL2019000485A1
CL2019000485A1 CL2019000485A CL2019000485A CL2019000485A1 CL 2019000485 A1 CL2019000485 A1 CL 2019000485A1 CL 2019000485 A CL2019000485 A CL 2019000485A CL 2019000485 A CL2019000485 A CL 2019000485A CL 2019000485 A1 CL2019000485 A1 CL 2019000485A1
Authority
CL
Chile
Prior art keywords
functional capacity
pridopidine
treatment
patient
functional decline
Prior art date
Application number
CL2019000485A
Other languages
English (en)
Inventor
Michael Hayden
Spyridon Papapetropoulos
Juha-Matti Savola
Eli Eyal
Beth Borowsky
Igor D Grachev
Original Assignee
Prilenia Therapeutics Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Therapeutics Dev Ltd filed Critical Prilenia Therapeutics Dev Ltd
Publication of CL2019000485A1 publication Critical patent/CL2019000485A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTA INVENCIÓN PROPORCIONA UN MÉTODO PARA MANTENER LA CAPACIDAD FUNCIONAL, MEJORAR LA CAPACIDAD FUNCIONAL O RETARDAR LA DISMINUCIÓN DE LA CAPACIDAD FUNCIONAL EN UN PACIENTE HUMANO QUE COMPRENDE ADMINISTRAR PERIÓDICAMENTE POR VÍA ORAL AL PACIENTE UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE PRIDOPIDINA DE MANERA QUE SE ADMINISTRE UNA DOSIS DE 90-225 MG DE PRIDOPIDINA AL PACIENTE POR DÍA, PARA MANTENER ASÍ LA CAPACIDAD FUNCIONAL, MEJORAR LA CAPACIDAD FUNCIONAL O RETARDAR LA DISMINUCIÓN DE LA CAPACIDAD FUNCIONAL EN EL PACIENTE HUMANO.
CL2019000485A 2016-08-24 2019-02-22 Uso de pridopidina para el tratamiento de la disminución funcional. CL2019000485A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395263P 2016-09-15 2016-09-15
US201662411511P 2016-10-21 2016-10-21
US201662416685P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
CL2019000485A1 true CL2019000485A1 (es) 2019-07-12

Family

ID=61241181

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000485A CL2019000485A1 (es) 2016-08-24 2019-02-22 Uso de pridopidina para el tratamiento de la disminución funcional.
CL2019003924A CL2019003924A1 (es) 2016-08-24 2019-12-31 Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003924A CL2019003924A1 (es) 2016-08-24 2019-12-31 Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).

Country Status (11)

Country Link
US (1) US11207310B2 (es)
EP (1) EP3504187A4 (es)
JP (2) JP6912574B2 (es)
CN (2) CN109923102B (es)
AU (2) AU2017315783C1 (es)
BR (1) BR112019003732A2 (es)
CA (2) CA3035092C (es)
CL (2) CL2019000485A1 (es)
IL (1) IL311081A (es)
MX (2) MX2019002265A (es)
WO (1) WO2018039477A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3503890A4 (en) * 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
WO2018039477A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
WO2018052772A1 (en) 2016-09-15 2018-03-22 Boehringer Ingelheim International Gmbh Heteroaryl carboxamide compounds as inhibitors of ripk2
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT
EA202193190A1 (ru) * 2019-06-12 2022-03-24 Прилиния Ньюротерапьютикс Лтд. Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
AU2021266476A1 (en) * 2020-05-04 2022-11-24 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective S1R agonist

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
CN101056854B (zh) 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
DOP2006000273A (es) 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070286902A1 (en) 2006-06-07 2007-12-13 Abrika Pharmaceuticals Dosage forms comprising a short acting sedative-hypnotic or salt thereof
RU2470013C2 (ru) 2007-04-12 2012-12-20 НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов
WO2010008486A2 (en) * 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
EP2480218B1 (en) 2009-09-24 2020-05-27 Capsugel Belgium NV Acid resistant capsules
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130216856A1 (en) 2010-07-02 2013-08-22 Marco Burtchen Mechanical component and method of surface hardening
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
WO2012159079A1 (en) 2011-05-18 2012-11-22 The Parkinson's Institute Assay to determine lrrk2 activity in parkinson's disease
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
AU2013323133A1 (en) 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease
IN2015DN03219A (es) 2012-09-27 2015-10-02 Teva Pharma
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
ES2911800T3 (es) 2014-01-22 2022-05-20 Prilenia Neurotherapeutics Ltd Formulaciones de liberación modificada de pridopidina
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US10603311B2 (en) * 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CA3015512C (en) 2016-02-24 2024-01-16 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
EP3503890A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
WO2018039477A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
JP2019529411A (ja) 2016-09-15 2019-10-17 プリレニア ニューロセラピューティクス リミテッド 不安症およびうつ病の治療のためのプリドピジンの使用
CA3036984C (en) 2016-09-16 2023-07-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating rett syndrome
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
WO2018136600A1 (en) 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of fragile x syndrome
CA3072882C (en) 2017-08-14 2023-03-21 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
AU2018326596B2 (en) 2017-08-30 2021-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine

Also Published As

Publication number Publication date
AU2020223736A1 (en) 2020-09-17
US20180055832A1 (en) 2018-03-01
JP2019524898A (ja) 2019-09-05
CA3035092A1 (en) 2018-03-01
AU2017315783B2 (en) 2020-05-28
NZ751156A (en) 2021-01-29
BR112019003732A2 (pt) 2020-02-18
MX2022003072A (es) 2022-06-17
CA3151507C (en) 2024-05-28
JP2021119186A (ja) 2021-08-12
CN109923102A (zh) 2019-06-21
JP6912574B2 (ja) 2021-08-04
CA3151507A1 (en) 2018-03-01
US11207310B2 (en) 2021-12-28
AU2017315783C1 (en) 2020-12-24
WO2018039477A1 (en) 2018-03-01
EP3504187A1 (en) 2019-07-03
CN109923102B (zh) 2022-11-15
CN115671103A (zh) 2023-02-03
MX2019002265A (es) 2019-10-30
AU2020223736B2 (en) 2022-04-07
AU2017315783A1 (en) 2019-04-11
CL2019003924A1 (es) 2020-05-29
CA3035092C (en) 2022-05-31
EP3504187A4 (en) 2020-05-06
IL311081A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
CO2017011437A2 (es) Composiciones de nanopartículas para terapia sostenida
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
CL2015003117A1 (es) Modificaciones en la estructura cristalina
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
GT201400111A (es) Triazolopiridinas sustituidas
PE20181207A1 (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
CO2017008148A2 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2015002835A1 (es) Nuevos derivados de piridina
CL2018001092A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CR20170264A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
CO2019008657A2 (es) Composición intranasal que comprende betahistina
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação